Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722239 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Antithrombotics in Acute Ischemic Stroke - The Clot Thickens
Datamonitor, April 2003, Pages: 63


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction
Despite an incidence of over 1.7m in the seven major markets, the thrombolytic Activase (alteplase) is the only drug approved for ischemic stroke outside of Japan and has a three-hour therapeutic window, which means that only a minority of patients are eligible for therapy. Therefore, ischemic stroke is a potentially lucrative target market for pharmaceutical companies.

Scope
Estimates of the current and future incidence of acute ischemic stroke in the seven major markets

Discussion of current status of therapy and identification of the unmet needs with greatest commercial potential

Profiles of antithrombotics being trialed in acute ischemic stroke, analyzing their strengths and weaknesses in this indication

Comparative assessment of antithrombotics in development for stoke, in relation to alteplase, in terms of satisfaction of unmet need and potential

Report Highlights
With an estimated incidence of over 1.7m ischemic strokes in 2002 in the seven major markets and high unmet need, with just one drug approved outside of Japan for ischemic stroke, there is significant impetus for companies to trial agents in this indication.

In terms of developing safe and effective therapies for ischemic stroke, the greatest obstacle lies in extending the therapeutic window from the currently limited three hours to at least 6-12 hours.

In the absence of regenerative therapy, companies need to look beyond conventional single drug approaches and investigate which combinations of drugs and/or devices can achieve the best possible results in acute ischemic stroke.

Reasons to Purchase
Identify strategies for increasing the patient potential of antithrombotics in development for stroke

Identify the unmet needs that exist in the treatment of acute ischemic stroke and the extent that are likely to be met over the coming years

Understand which antithrombotics currently in development for acute ischemic stroke are the most promising and why



Customers who bought this item also bought

Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need

Stakeholder Insight: Acute Stroke - TPA Spurs Infrastructure Changes for the Better

Target Product Profiles 2008: Physician Insights on Key Attributes - Acute Ischemic Stroke

Acute Stroke - Considerable Unmet Need is Balanced by Substantial Commercial Risk

Drugs, Devices and Procedures of Tomorrow: Acute Stroke - Chasing the need for speed

TPA in Stroke: Treatment Patterns and Potential

Treatment Algorithms 2001: Stroke - Time is Brain

Acute Stroke - Symptom Awareness Will Reduce Headache

Neuroprotection in Stroke - Protecting the Brain Sells

Strategic Perspectives: Marketed Antithrombotics - Plavix Adopts Lovenox's Developmental Defense Strategy

Stroke: Treatments and Prescribing Practices - A Global Survey 2009

Pipeline Insight: Antithrombotics - Reaching The Untreated Prophylaxis Market



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds